Twist Bioscience is a synthetic biology business that uses a proprietary silicon chip to "write" DNA at a scale and cost that traditional methods cannot match. It generated $0.38 billion in revenue in fiscal 2025, growing roughly 23% over the prior year as more biotech and industrial companies moved their DNA orders to its platform. The company recently reported its 13th consecutive quarter of sequential growth and is now on the verge of reaching adjusted profitability for the first time.
The investment thesis on Twist Bioscience is that its silicon-based synthesis platform provides a permanent cost and throughput advantage that competitors using plastic plates simply cannot close. This technology allows Twist to miniaturize the chemical process of making DNA, using far fewer expensive reagents to produce a higher volume of custom genes.
We think Twist is successfully transitioning from a high-growth science project into a durable industrial platform with a widening competitive lead. The company has proven it can take share in a difficult funding environment, which suggests its cost advantage is a real necessity for its customers rather than a luxury.
What does it do?
Twist Bioscience is a hypergrowth business that earns money by selling custom-made DNA, which it manufactures using a unique silicon-based writing platform. Traditional DNA synthesis relies on plastic plates that are bulky and expensive to use; Twist instead "prints" thousands of tiny strands of DNA onto a single silicon chip the size of a postage stamp. This process uses 99% less chemical reagent than the old way, allowing Twist to sell high-quality synthetic genes, libraries, and NGS tools at a fraction of the market price. Customers submit their desired DNA sequences online, and Twist ship the physical DNA in tubes or plates within weeks.
Where does revenue come from?
Revenue is split between selling the DNA itself and providing the specialized tools used to read and analyze it. The Next-Generation Sequencing (NGS) segment is the largest, providing target enrichment kits that help researchers focus on specific parts of the genome. The DNA Synthesis and Protein Solutions (DSPS) segment follows, which includes custom genes, "oligo" pools, and antibody libraries used for drug discovery. Geographically, Twist serves a global market with a significant presence in North America, Europe, and Asia.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Twist Bioscience serves approximately 2,583 active customers across the healthcare, industrial chemicals, agriculture, and academic research sectors. In the second quarter of fiscal 2026, the company physically shipped roughly 300,000 custom genes, a sharp increase from 227,000 in the same period a year ago. These customers range from small biotech startups needing a single custom gene to global pharmaceutical giants like Amazon Web Services, which recently partnered with Twist for AI-powered drug discovery. The company also serves clinical research labs through its TrueAmp and PCR-Free library preparation kits, which are essential for diagnostic testing.
What gives it staying power?
Twist’s staying power comes from its proprietary silicon platform, which creates a massive cost advantage that rivals cannot easily replicate without starting over. By miniaturizing the process, Twist achieves a throughput that is orders of magnitude higher than competitors. This scale makes it the "low-cost provider" in a market where researchers are increasingly budget-constrained.
Where is it headed?
Twist is currently headed toward a future where it not only writes DNA for research but also uses it as a medium for long-term data storage. While still in the early stages, management is investing in "DNA Data Storage" to compete with traditional hard drives and tape for archiving data. If this works, Twist would move beyond the biotech market and into the multi-billion dollar enterprise storage industry.
Verdict: Revenue growth remains impressively consistent despite a tough biotech funding environment. The company delivered its 13th straight quarter of sequential growth in Q2 FY2026, reaching $110.7 million. This steady climb confirms that Twist is taking market share from legacy providers who cannot match its silicon-driven pricing.
Verdict: Cash quality is improving as the business scales toward self-sustainability. While Twist is still burning cash, the net loss per share improved from -$3.60 in 2024 to -$1.30 in 2025. Management’s commitment to reaching adjusted EBITDA breakeven by Q4 FY2026 is a credible signal that the period of heavy, unconstrained spending is ending.
Verdict: The balance sheet provides enough runway to reach the next stage of growth without immediate dilution. With $172 million in cash and short-term investments as of March 2026, Twist has several quarters of liquidity at its current burn rate. The low debt-to-equity ratio of 0.21x gives the company flexibility if it needs to tap credit markets rather than selling more stock.
Twist Bioscience is a high-growth platform that is finally matching its technical leadership with financial discipline.
Gross margins have expanded to 51.6% in the most recent quarter, proving that the silicon writing platform gets more efficient as volume rises. This 2-point improvement over the prior year suggests the company can maintain its low prices while still capturing more profit from every gene shipped.
Sales and administrative expenses remain high at $76.1 million, which is more than half of total revenue. The risk is that the cost of acquiring and supporting thousands of small customers might offset the technical savings from the silicon manufacturing process.
The synthetic biology market is roughly $15 billion today and is growing approximately 18% annually as DNA becomes a core "software" for drug discovery and industrial materials. It is on track to exceed $30 billion by 2029. This is a fundamentally strong industry where proprietary manufacturing platforms create a structural cost advantage that allows leaders to expand margins while lowering prices. Twist stands as the primary disruptor in this market, holding a dominant position in the high-volume, low-cost "DNA writing" niche that gives it a massive runway as biotech research shifts toward larger-scale experiments.
The market is shifting from a fragmented collection of local providers to a more consolidated structure dominated by a few high-scale players. Pricing power is currently held by those who can deliver the highest accuracy at the lowest cost per base pair.
Danaher’s IDT is the incumbent giant, using vast distribution and traditional methods to defend its territory, while GenScript provides aggressive competition from a lower-cost manufacturing base in China. Smaller players like DNA Script are attempting to disrupt the market by putting the "writer" directly on a scientist’s desk, though these benchtop systems cannot yet match the scale or cost of Twist’s centralized silicon factory. The most dangerous threat comes from IDT and GenScript using their massive cash reserves to subsidize price cuts that could stall Twist's momentum.
Twist is clearly gaining share, as evidenced by its 13 consecutive quarters of sequential growth and a nearly 20% rise in quarterly revenue. Twist’s growth is consistently outpacing the broader biotech sector, proving its silicon platform is winning the price-to-performance battle.
Twist’s primary protection is its proprietary silicon platform, which allows it to synthesize DNA at a scale 1,000 times higher than traditional plastic plates. This IP is protected by extensive patents and, more importantly, by the sheer manufacturing complexity of "writing" DNA on silicon chips at high density. The single most compelling proof is Twist’s ability to grow revenue 19% YoY while expanding gross margins to over 51%.
The combination of 52% gross margins and a rising customer base of over 2,500 accounts proves this is a real structural advantage rather than a temporary lead. While ROIC is currently negative due to high R&D and scaling costs, the upward trend in unit economics suggests a durable moat is forming as Twist becomes the "foundry" for the synthetic biology industry.
The forward-looking verdict is that the moat is strengthening as Twist hits the scale required to make its DNA data storage and antibody discovery services economically viable.
13 consecutive quarters of sequential revenue growth.
$171.1M litigation settlement reached to clear legal overhang.
Emily Leproust is a co-founder with a significant personal stake.
Capital Allocation Track Record
Emily Leproust and her team have demonstrated exceptional strategic judgment by pivoting the company toward profitability just as the biotech funding environment tightened. They have successfully navigated 13 straight quarters of growth without needing a massive, dilutive capital raise during the market downturn. This ability to maintain a high-growth trajectory while simultaneously expanding gross margins by 200 basis points in a single year shows a management team that deeply understands its unit economics.
The primary key-person risk is concentrated in CEO Emily Leproust, whose vision for silicon-based DNA synthesis is the cornerstone of the entire business. While Twist has built a capable bench with President Patrick Finn and a new CIO, Leproust’s dual role as founder and lead scientist makes her difficult to replace. Governance is generally sound, though the company’s recent $17.1 million litigation settlement highlights the inherent volatility and legal risks associated with disrupting a complex, highly patented industry.
Twist Bioscience is projected to reach positive annual EPS in FY2029 as the scaling of its silicon DNA platform drives operating leverage. Our base case assumes revenue compounds at 18% annually through 2031, driven by continued NGS market share gains and the commercialization of DNA data storage. We project gross margins to stabilize around 54% as high-margin antibody discovery services become a larger portion of the mix, leading to an EPS of $2.35 by FY2031.
Adjusted EBITDA breakeven by Q4 FY2026 confirms model. Reaching breakeven would prove Twist can self-fund its growth and remove the constant threat of dilutive capital raises.
DNA Data Storage matures into a commercial product line. Moving from research to a viable enterprise storage product would expand Twist's addressable market from billions to tens of billions.
AI partnership with AWS accelerates antibody discovery revenue. Deeply embedding Twist's "wet lab" services into AWS's AI drug discovery tools creates a high-margin recurring revenue stream.
Large incumbents use price wars to protect market share. If Danaher or GenScript aggressively cut prices, Twist's path to profitability could be delayed by the need to match them.
DNA data storage fails to reach cost parity with tape. If the cost of reading and writing DNA for storage doesn't fall fast enough, the multi-year investment could be written off.
Slowdown in biotech funding reduces demand for custom genes. A prolonged venture capital drought for biotech startups would hit Twist's core DNA synthesis customer base.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use an EV/Revenue approach with a forward-looking margin bridge. This framework is the most reliable for Twist because the company is in a rapid growth phase and approaching a GAAP profitability inflection; traditional P/E ratios are currently distorted by the transition from losses to earnings.
Applying a 12x multiple to our FY2027 revenue estimate of $520 million, plus $20 million in net cash, results in a $101 fair value. The 12x multiple sits at the higher end of the life sciences peer range (Ginkgo Bioworks at 8x, typical biotech tools at 10x) because Twist’s 50%+ gross margins and silicon-moat justify a premium. We divide the resulting $6.26 billion equity value by 62.3 million diluted shares to reach our per-share target.
A peer-anchored Price-to-Sales (P/S) cross-check produces a fair value of $98—within 3% of our primary answer, confirming the valuation. Using the current TTM P/S of 14.3x as a ceiling and a mature-tech multiple of 8.0x as a floor, a 12.0x blended multiple on FY2027 revenue aligns with historical trading bands during periods of high execution. This tight agreement between methods suggests the market is accurately pricing current growth but may be underestimating the leverage from margin expansion.
We're assuming Twist generates $520 million in revenue for fiscal year 2027. This represents a roughly 18% growth rate over FY2026 estimates, which is consistent with the company's 12-quarter streak of revenue expansion and the increasing adoption of Next-Generation Sequencing (NGS) tools in clinical diagnostics.
We're assuming gross margins remain structurally above the 50% threshold. Management has already improved margins from 31% to over 53% in two years; our assumption of 52% for FY2027 is supported by the fact that 75-80% of incremental revenue now drops directly to profit as the "Factory of the Future" reaches higher utilization.
We're assuming Next-Generation Sequencing (NGS) remains the primary growth engine at 55% of total revenue. The growth in liquid biopsy and minimal residual disease (MRD) testing creates a steady, recurring demand for Twist’s library preparation kits, providing the cash flow necessary to fund the longer-term DNA data storage optionality.
The biggest risk is the failure to achieve adjusted EBITDA breakeven by the fourth quarter of fiscal 2026. Missing this self-imposed deadline would shatter investor confidence in the scalability of the silicon-writing platform, likely compressing the forward revenue multiple from 12x to 7x and knocking roughly $42 off the fair value. Watch the "Loss from Operations" line in the upcoming Q3 report for any widening of the current -$45.8M gap.
Bear case ($65): Gross margins contract below 48% due to pricing pressure in the NGS Tools segment or manufacturing inefficiencies at the Wilsonville facility; or Management fails to reach adjusted EBITDA breakeven by Q4 FY2026, forcing a dilutive capital raise at unfavorable terms.
Bull case ($145): DNA data storage pilot programs transition to commercial licensing agreements earlier than the current 2028-2030 roadmap suggests; or Revenue growth re-accelerates toward 30% as AI-driven protein design workflows dramatically increase the demand for high-fidelity synthetic genes.
Clearthesis wrote this report from 39 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on July 9, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.